CellSearch cancer patient monitor cleared by FDA:
This article was originally published in Clinica
CellSearch, Immunicon's tumour cell detection kit, has been cleared for sale by the US FDA via the 510(k) route. It is now approved for monitoring patients with metastatic colorectal cancer; in 2004 it gained US clearance for in vitro diagnostic use in patients with metastatic breast cancer. Evaluation of circulating tumour cell (CTC) count at any time during the course of disease allows assessment of patient prognosis and is predictive of progression-free and overall survival. CellSearch is exclusively marketed by Veridex, a subsidiary of Johnson & Johnson, in the cancer field. It is CE-marked in the EU, and final Japanese approval is pending. The Huntingdon Valley, Pennsylvania company has also filed for US approval for prostate cancer, which it expects next year.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.